Recent analysis of Amdocs (DOX) has drawn attention to declining annual sales and earnings growth that trails peers, prompting investors to reassess expectations and sentiment around the stock’s near term prospects.

At a share price of $51.22, Amdocs has seen its 90 day share price return fall 20.93%, and its 1 year total shareholder return decline 40.99%, signalling fading momentum as investors reassess growth and risk.

If you are reassessing Amdocs and want to see where capital may be moving next, it may help to compare it with other AI focused software players using the Simply Wall St screener for 54 AI infrastructure stocks

Amdocs now trades at a level that reflects a lot of recent disappointment, so the question is whether most of the downside has already played out or if the current valuation still leaves room for potential gains.

Most Popular Narrative: 37.6% Undervalued

At a last close of $51.22, the most followed narrative on Amdocs points to a fair value of $82.03, which frames the recent share price weakness in a very different light.

Financially, the company is characterized by strong recurring revenue streams, highlighted by a high renewal rate for managed services, which account for approximately 65% of total revenue, and a substantial 12-month backlog of $4.28 billion. This stability allows the company to pursue a disciplined capital allocation strategy, featuring consistent dividend growth and significant share repurchases.

Curious what underpins that $82.03 fair value for Amdocs at a discount rate just above 9%? The narrative leans heavily on recurring revenue, steady margins and an earnings profile that supports a richer profit multiple than the current market price suggests. The key levers are all quantified, but the balance between growth, profitability and cash returns to shareholders is more nuanced than the headline figure alone.

Result: Fair Value of $82.03 (UNDERVALUED)

However, investors still need to weigh risks, including slower spending by communications customers or execution missteps as Amdocs shifts more deeply into GenAI-focused offerings.

Next Steps

If the split sentiment around Amdocs has you on the fence, move quickly to check the underlying drivers yourself and weigh them against the 5 key rewards

Looking for more investment ideas beyond Amdocs?

If you are reassessing Amdocs, do not stop there. Use the Simply Wall St screener to uncover fresh opportunities that could better fit your portfolio goals.

• Target potential mispricing across the market by scanning companies screened as high quality yet overlooked through the screener containing 20 high quality undiscovered gems.
• Strengthen the core of your holdings by focusing on companies with robust financial foundations using the solid balance sheet and fundamentals stocks screener (49 results).
• Prioritise stability and capital protection by filtering for companies assessed with lower overall risk profiles through the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.